However, the BTG3 and BTG4 increased mainly correlated with survival disadvantages, where BTG3 predicted poor prognosis for ACC, HNSC, LGG, and BTG4 predicted poor prognosis for HNSC, KIRC, MESO, UCS (Supplement Fig. 1; Table S2). This evidence concerns the gene BTG3 and adrenal cortex carcinoma.